Literature DB >> 22878877

Shared Pseudomonas aeruginosa genotypes are common in Australian cystic fibrosis centres.

Timothy J Kidd1, Kay A Ramsay, Honghua Hu, Guy B Marks, Claire E Wainwright, Peter T Bye, Mark R Elkins, Philip J Robinson, Barbara R Rose, John W Wilson, Keith Grimwood, Scott C Bell.   

Abstract

Recent molecular-typing studies suggest cross-infection as one of the potential acquisition pathways for Pseudomonas aeruginosa in patients with cystic fibrosis (CF). In Australia, there is only limited evidence of unrelated patients sharing indistinguishable P. aeruginosa strains. We therefore examined the point-prevalence, distribution, diversity and clinical impact of P. aeruginosa strains in Australian CF patients nationally. 983 patients attending 18 Australian CF centres provided 2887 sputum P. aeruginosa isolates for genotyping by enterobacterial repetitive intergenic consensus-PCR assays with confirmation by multilocus sequence typing. Demographic and clinical details were recorded for each participant. Overall, 610 (62%) patients harboured at least one of 38 shared genotypes. Most shared strains were in small patient clusters from a limited number of centres. However, the two predominant genotypes, AUST-01 and AUST-02, were widely dispersed, being detected in 220 (22%) and 173 (18%) patients attending 17 and 16 centres, respectively. AUST-01 was associated with significantly greater treatment requirements than unique P. aeruginosa strains. Multiple clusters of shared P. aeruginosa strains are common in Australian CF centres. At least one of the predominant and widespread genotypes is associated with increased healthcare utilisation. Longitudinal studies are now needed to determine the infection control implications of these findings.

Entities:  

Keywords:  Cross-infection; PCR; molecular typing

Mesh:

Year:  2012        PMID: 22878877     DOI: 10.1183/09031936.00060512

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  24 in total

1.  Genotypic diversity of Pseudomonas aeruginosa in cystic fibrosis siblings in Qatar using AFLP fingerprinting.

Authors:  A Abdul Wahab; S J Taj-Aldeen; F Hagen; S Diophode; A Saadoon; J F Meis; C H Klaassen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-01       Impact factor: 3.267

2.  Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain.

Authors:  Michael D Parkins; Bryan A Glezerson; Christopher D Sibley; Kristen A Sibley; Jessica Duong; Swathi Purighalla; Christopher H Mody; Matthew L Workentine; Douglas G Storey; Michael G Surette; Harvey R Rabin
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

3.  Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis.

Authors:  J Manos; H Hu; B R Rose; C E Wainwright; I B Zablotska; J Cheney; L Turnbull; C B Whitchurch; K Grimwood; C Harmer; S N Anuj; C Harbour
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-07-07       Impact factor: 3.267

Review 4.  Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Authors:  Michael D Parkins; Ranjani Somayaji; Valerie J Waters
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

5.  Isolation of Phage Lysins That Effectively Kill Pseudomonas aeruginosa in Mouse Models of Lung and Skin Infection.

Authors:  Assaf Raz; Anna Serrano; Anaise Hernandez; Chad W Euler; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

6.  Anti-LPS IgA and IgG Can Inhibit Serum Killing of Pseudomonas aeruginosa in Patients with Cystic Fibrosis.

Authors:  Amy Pham; Emma L Ledger; Carrie F Coggon; Ian R Henderson; David W Reid; Scott C Bell; Daniel J Smith; Timothy J Wells
Journal:  Infect Immun       Date:  2021-08-30       Impact factor: 3.441

7.  What Makes Pseudomonas aeruginosa a Pathogen?

Authors:  Burkhard Tümmler
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

8.  Developing an international Pseudomonas aeruginosa reference panel.

Authors:  Anthony De Soyza; Amanda J Hall; Eshwar Mahenthiralingam; Pavel Drevinek; Wieslaw Kaca; Zuzanna Drulis-Kawa; Stoyanka R Stoitsova; Veronika Toth; Tom Coenye; James E A Zlosnik; Jane L Burns; Isabel Sá-Correia; Daniel De Vos; Jean-Paul Pirnay; Timothy J Kidd; David Reid; Jim Manos; Jens Klockgether; Lutz Wiehlmann; Burkhard Tümmler; Siobhán McClean; Craig Winstanley
Journal:  Microbiologyopen       Date:  2013-11-11       Impact factor: 3.139

Review 9.  Year in review 2013: Lung cancer, respiratory infections, tuberculosis, cystic fibrosis, pleural diseases, bronchoscopic intervention and imaging.

Authors:  Chi Chiu Leung; José M Porcel; Kazuhisa Takahashi; Marcos I Restrepo; Pyng Lee; Claire Wainwright
Journal:  Respirology       Date:  2014-02-21       Impact factor: 6.424

10.  Phenotypic and Genotypic Comparison of Epidemic and Non-Epidemic Strains of Pseudomonas aeruginosa from Individuals with Cystic Fibrosis.

Authors:  Jessica Duong; Sean C Booth; Nathan K McCartney; Harvey R Rabin; Michael D Parkins; Douglas G Storey
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.